~~<i id='C158EAE4F9'><strike id='C158EAE4F9'><tt id='C158EAE4F9'><pre id='C158EAE4F9'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：hotspot 2025-09-28 15:36:05 Page View：528

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： SCOTUS questions limit to govt efforts to fight misinformation
Next article： Drug repurposing or repositioning? The language matters

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

FDA rejects Alnylam's heart disease treatment over insufficient data

KristofferTripplaar/SipaUSA/APTheFoodandDrugAdministrationrejectedanAlnylamPharmaceuticals’therapyfo

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

A Q&A with the global head of Boehringer Ingelheim's innovation unit

MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr